Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV001942501 | SCV002130745 | uncertain significance | Fanconi anemia | 2022-05-15 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 664 of the SLX4 protein (p.Pro664Thr). This variant is present in population databases (rs759223029, gnomAD 0.008%). This variant has not been reported in the literature in individuals affected with SLX4-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Fulgent Genetics, |
RCV002478149 | SCV002776325 | uncertain significance | Fanconi anemia complementation group P | 2022-04-04 | criteria provided, single submitter | clinical testing | |
| Ambry Genetics | RCV004039896 | SCV004953280 | uncertain significance | Inborn genetic diseases | 2024-01-30 | criteria provided, single submitter | clinical testing | The c.1990C>A (p.P664T) alteration is located in exon 9 (coding exon 8) of the SLX4 gene. This alteration results from a C to A substitution at nucleotide position 1990, causing the proline (P) at amino acid position 664 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |